Bio-Techne To Present At The Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will have its CEO, Chuck Kummeth, present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. EDT. The presentation will be available through a live webcast on the company's Investor Relations website. Bio-Techne specializes in developing high-quality purified proteins and reagent solutions, generating approximately $739 million in net sales for FY 2020. With about 2,600 employees globally, the company plays a critical role in biomedical research and clinical diagnostics.

MINNEAPOLIS, May 19, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has approximately 2,600 employees worldwide.

Contact:	David Clair, Senior Director, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-jefferies-virtual-healthcare-conference-301294284.html

SOURCE Bio-Techne Corporation

FAQ

When will Bio-Techne present at the Jefferies Virtual Healthcare Conference?

Bio-Techne will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. EDT.

Who is presenting for Bio-Techne at the Jefferies Conference?

Chuck Kummeth, the CEO of Bio-Techne, will be presenting at the conference.

How can I access the Bio-Techne presentation at the conference?

The presentation will be available via a live webcast on Bio-Techne's Investor Relations website.

What are Bio-Techne's main business areas?

Bio-Techne focuses on high-quality purified proteins, reagent solutions, diagnostics, and genomic tools.

What was Bio-Techne's net sales figure for fiscal year 2020?

Bio-Techne generated approximately $739 million in net sales for fiscal year 2020.